Literature DB >> 27665354

Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Robert G Schaut1, Tara L Grinnage-Pulley2, Kevin J Esch3, Angela J Toepp1, Malcolm S Duthie4, Randall F Howard4, Steven G Reed4, Christine A Petersen5.   

Abstract

Visceral leishmaniasis (VL), caused by infection with the obligate intracellular protozoan parasite Leishmania infantum, is a fatal disease of dogs and humans. Protection against VL requires a T helper 1 (Th1) skewed CD4+ T response, but despite this knowledge, there are currently no approved-to-market vaccines for humans and only three veterinary-use vaccines globally. As VL progresses from asymptomatic to symptomatic, L. infantum-specific interferon gamma (IFNγ) driven-Th1 responses become dampened and a state of immune exhaustion established. T cell exhaustion and other immunoregulatory processes, starting during asymptomatic disease, are likely to hinder vaccine-induced responses if vaccine is administered to infected, but asymptomatic and seronegative, individuals. In this study we evaluated how immune exhaustion, shown previously by our group to worsen in concert with VL progression, effected the capacity of vaccine candidate antigen/toll-like receptor (TLR) agonist combinations to promote protective CD4+ T cell responses during progressive VL. In conjunction with Th1 responses, we also evaluated concomitant stimulation of immune-balanced IL-10 regulatory cytokine production by these vaccine products in progressive VL canine T cells. Vaccine antigen L111f in combination with TLR agonists significantly recovered CD4+ T cell IFNγ intracellular production in T cells from asymptomatic VL dogs. Vaccine antigen NS with TLR agonists significantly recovered CD4+ T cell production in both endemic control and VL dogs. Combinations of TLR agonists and vaccine antigens overcame L. infantum induced cellular exhaustion, allowing robust Th1 CD4+ T cell responses from symptomatic dogs that previously had dampened responses to antigen alone. Antigen-agonist adjuvants can be utilized to promote more robust vaccine responses from infected hosts in endemic areas where vaccination of asymptomatic, L. infantum-infected animals is likely.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Adjuvants; CD4(+) T cells; Cytokines; Leishmania (L.) infantum; Toll-like receptor agonist

Mesh:

Substances:

Year:  2016        PMID: 27665354      PMCID: PMC5053902          DOI: 10.1016/j.vaccine.2016.09.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  63 in total

1.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

Review 2.  Leishmaniasis: complexity at the host-pathogen interface.

Authors:  Paul Kaye; Phillip Scott
Journal:  Nat Rev Microbiol       Date:  2011-07-11       Impact factor: 60.633

3.  Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.

Authors:  Jacqueline Araújo Fiuza; Sreenivas Gannavaram; Helton da Costa Santiago; Angamuthu Selvapandiyan; Daniel Menezes Souza; Lívia Silva Araújo Passos; Ludmila Zanandreis de Mendonça; Denise da Silveira Lemos-Giunchetti; Natasha Delaqua Ricci; Daniella Castanheira Bartholomeu; Rodolfo Cordeiro Giunchetti; Lilian Lacerda Bueno; Rodrigo Correa-Oliveira; Hira L Nakhasi; Ricardo Toshio Fujiwara
Journal:  Vaccine       Date:  2014-12-01       Impact factor: 3.641

Review 4.  Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?

Authors:  Manu Vanaerschot; Franck Dumetz; Syamal Roy; Alicia Ponte-Sucre; Jorge Arevalo; Jean-Claude Dujardin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-05-06       Impact factor: 5.091

Review 5.  Vaccines for leishmaniasis in the fore coming 25 years.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Vaccine       Date:  2008-01-30       Impact factor: 3.641

6.  Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Authors:  Rhea N Coler; Sylvie Bertholet; Magdalini Moutaftsi; Jeff A Guderian; Hillarie Plessner Windish; Susan L Baldwin; Elsa M Laughlin; Malcolm S Duthie; Christopher B Fox; Darrick Carter; Martin Friede; Thomas S Vedvick; Steven G Reed
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

7.  Efficacy of Recombinant Canine Distemper Virus Expressing Leishmania Antigen against Leishmania Challenge in Dogs.

Authors:  Ryuichi Miura; Takanori Kooriyama; Misako Yoneda; Akiko Takenaka; Miho Doki; Yasuyuki Goto; Chizu Sanjoba; Yasuyuki Endo; Tomoko Fujiyuki; Akihiro Sugai; Kyoko Tsukiyama-Kohara; Yoshitsugu Matsumoto; Hiroki Sato; Chieko Kai
Journal:  PLoS Negl Trop Dis       Date:  2015-07-10

8.  From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Authors:  Rhea N Coler; Malcolm S Duthie; Kimberly A Hofmeyer; Jeffery Guderian; Lakshmi Jayashankar; Julie Vergara; Tom Rolf; Ayesha Misquith; John D Laurance; Vanitha S Raman; H Remy Bailor; Natasha Dubois Cauwelaert; Steven J Reed; Aarthy Vallur; Michelle Favila; Mark T Orr; Jill Ashman; Prakash Ghosh; Dinesh Mondal; Steven G Reed
Journal:  Clin Transl Immunology       Date:  2015-04-10

9.  Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahereh Taheri; Farnaz Zahedifard; Yasaman Taslimi; Fatemeh Doustdari; Azam Bolhassani; Delaram Doroud; Hiva Azizi; Kazem Heidari; Mohammad Vasei; Nabiollah Namvar Asl; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2013-04-18

10.  Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis.

Authors:  Jorge Miret; Evaldo Nascimento; Weverton Sampaio; João Carlos França; Ricardo Toshio Fujiwara; André Vale; Edelberto Santos Dias; Edvá Vieira; Roberto Teodoro da Costa; Wilson Mayrink; Antonio Campos Neto; Steven Reed
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

View more
  11 in total

1.  Eosinophils Affect Antibody Isotype Switching and May Partially Contribute to Early Vaccine-Induced Immunity against Coxiella burnetii.

Authors:  Lindsey Ledbetter; Rama Cherla; Catherine Chambers; Yan Zhang; Guoquan Zhang
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

2.  Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial.

Authors:  Angela Toepp; Mandy Larson; Tara Grinnage-Pulley; Carolyne Bennett; Michael Anderson; Molly Parrish; Hailie Fowler; Geneva Wilson; Katherine Gibson-Corely; Radhika Gharpure; Caitlin Cotter; Christine Petersen
Journal:  Am J Trop Med Hyg       Date:  2018-03-01       Impact factor: 2.345

3.  Prevalence of antinuclear antibodies and rheumatoid factor titers in dogs with arthritis secondary to leishmaniosis (Leishmania infantum).

Authors:  Theodora K Tsouloufi; Konstantina Theodorou; Michael J Day; Ioannis L Oikonomidis; Dimitrios Kasabalis; Mathios E Mylonakis; Manolis N Saridomichelakis; Maria Kritsepi-Konstantinou; Nectarios Soubasis
Journal:  J Vet Diagn Invest       Date:  2022-06-02       Impact factor: 1.569

Review 4.  The balancing act: Immunology of leishmaniosis.

Authors:  Angela J Toepp; Christine A Petersen
Journal:  Res Vet Sci       Date:  2020-02-11       Impact factor: 2.534

5.  Toll-like receptors 2, 4 and 7, interferon-gamma and interleukin 10, and programmed death ligand 1 transcripts in skin from dogs of different clinical stages of leishmaniosis.

Authors:  Laura Ordeix; Sara Montserrat-Sangrà; Pamela Martínez-Orellana; Marta Baxarias; Laia Solano-Gallego
Journal:  Parasit Vectors       Date:  2019-12-05       Impact factor: 3.876

6.  Immunoprophylactic Potential of a New Recombinant Leishmania infantum Antigen for Canine Visceral Leishmaniasis: An In Vitro Finding.

Authors:  Rômulo Pessoa-E-Silva; Lays Adrianne Mendonça Trajano-Silva; Victor Vaitkevicius-Antão; Wagner José Tenório Dos Santos; Franklin Barbalho Magalhães; Danielle Maria Nascimento Moura; Eiji Kevin Nakasone Nakasone; Virgínia Maria Barros de Lorena; Milena de Paiva-Cavalcanti
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

7.  Leishmania infantum xenodiagnosis from vertically infected dogs reveals significant skin tropism.

Authors:  Breanna M Scorza; Kurayi G Mahachi; Arin C Cox; Angela J Toepp; Adam Leal-Lima; Anurag Kumar Kushwaha; Patrick Kelly; Claudio Meneses; Geneva Wilson; Katherine N Gibson-Corley; Lyric Bartholomay; Shaden Kamhawi; Christine A Petersen
Journal:  PLoS Negl Trop Dis       Date:  2021-10-06

8.  Bayesian latent class models for identifying canine visceral leishmaniosis using diagnostic tests in the absence of a gold standard.

Authors:  Marie V Ozanne; Grant D Brown; Breanna M Scorza; Kurayi Mahachi; Angela J Toepp; Christine A Petersen
Journal:  PLoS Negl Trop Dis       Date:  2022-03-14

9.  The inflammatory cytokine effect of Pam3CSK4 TLR2 agonist alone or in combination with Leishmania infantum antigen on ex-vivo whole blood from sick and resistant dogs.

Authors:  Pamela Martínez-Orellana; Paulina Quirola-Amores; Sara Montserrat-Sangrà; Laura Ordeix; Joan Llull; Alejandra Álvarez-Fernández; Laia Solano-Gallego
Journal:  Parasit Vectors       Date:  2017-03-13       Impact factor: 3.876

10.  Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in L. infantum-infected dogs.

Authors:  Leopoldo F M Nascimento; Dayane Francisca Higino Miranda; Luana D Moura; Flaviane A Pinho; Guilherme Loureiro Werneck; Ricardo Khouri; Steven G Reed; Malcolm S Duthie; Aldina Barral; Manoel Barral-Netto; Maria S P Cruz
Journal:  Vaccine X       Date:  2019-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.